Please assess the completion status of the following clinical trial:

Trial Title: Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years.~* BMI\> 19kg/m2 and \<29kg/m2.~* Women of childbearing potential who are committed to use a medically effective contraception during their participation in the study, except hormonal contraceptives.~* Percentage of inhibition of platelet aggregation after stimulation with high basal 20 mM ADP and arachidonic acid 1.5 mM\> 70%.~* No clinically significant deviation on physical examination, ECG or laboratory values in laboratory tests.~* Signed informed consent~Exclusion Criteria:~* Smoking~* Drug abuse~* Pregnant or lactating~* Infection with Hepatitis B or C, or HIV~* Known drug allergies~* Family history of blood disorders or coagulation.~* History of disease that alters the absorption, metabolism or excretion of drugs, including jaundice.~* Personal history of bleeding and / or blood dyscrasias (especially hemophilia, hypoprothrombinemia), including vascular malformations reasonable suspicion.~* History of any medically relevant condition~* Background of major surgery in the last 3 months~* Prescription of chronic medication in the 14 days prior to study participation.~* Participation in another study involving the administration of an investigational product in the last 4 months or a product already on the market in the last three months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- prasugrel and acetylsalicylic (Type: ACTIVE_COMPARATOR): single dose of prasugrel 60 mg orally and 300 mg acetylsalicylic acid orally
- lysine acetylsalicylate and prasugrel (Type: EXPERIMENTAL): single dose of prasugrel 60 mg oral and lysine acetylsalicylate 450 mg intravenous

Based on this trial design, predict the completion outcome and termination type (if applicable).